Presentation on Thursday, September 3rd at 12:20 PM ET

LOS ANGELES, CA / ACCESSWIRE / August 27, 2020 / Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 12:20 PM ET. Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, will be presenting to a live audience and will be available for virtual one-on-one meetings with investors throughout the conference.

The online presentation will be webcast live and available for replay by following this link: https://www.webcaster4.com/Webcast/Page/2019/36835

The LD Micro 500 will be held September 1-4, 2020. Interested investors should contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information or you can register at this link: https://ld-micro-conference.events.issuerdirect.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD Micro.

The LD 500 will take place on September 1st – 4th, 2020.

View Aditx Therapeutics's profile here: http://www.ldmicro.com/profile/ADTX

Profiles powered by LD Micro – News Compliments of Accesswire

About Aditx Therapeutics

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit www.aditxt.com.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, risk factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

PCG Advisory
Jeff Ramson
Chief Executive Officer
646-762-4518
IR@aditxt.com
www.aditxt.com

SOURCE: Aditx Pharmaceuticals via LD Micro

ReleaseID: 603561

SEATTLE, WA / ACCESSWIRE / August 27, 2020 / ReelTime VR (OTC PINK:RLTR) confirmed that it has received an "Issue Notification" the United States Patent and Trademark Office.

The USPTO Notification specifies the projected patent number and issue date as 10761303 and 09/01/2020 respectfully. In addition, the notification makes a "Determination of Patent Term and Adjustment" under 35 U.S.C 154 (b) to be 247 days.

Barry Henthorn, CEO of ReelTime, stated: "This is particularly good news for ReelTime and its progress towards achieving a strong patent that covers a variety of uses. We are anxiously awaiting the final issuance which has been projected by the USPTO as 09/01/2020. Once the patent is fully issued, we will move forward with our planned enforcements and licensing opportunities."

Although the original technology allows any cell phone or other camera to instantaneously capture 360 X 360 Virtual Reality Video or pictures without any need for stitching, the patent provides protection from infringement from any capturing of a plurality of images utilizing at least one mirror. This spans a wide range of industries and uses.

The Patent application submitted 7/19/2017, successfully claims priority back to an earlier-filed provisional patent application to July 19, 2016. By linking a child to a parent through a priority claim, the child application benefits from the priority date of the parent.

The Simultaneous Spherical Panorama Image and Video Capturing System (code-named the "Periramascope"), is described in the pending patent application as a "360-degree image and capturing system having no lenses, a single lens, or a plurality of lenses. The device directs light from a sphere surrounding the device to a single reflected aggregate image that is then transformed into a full 360 X 360 spherical image or any subset thereof…"

About Bold Patents Expertise in Patent Law: www.boldip.com – Our main focus is to help inventors and business owners secure top-quality patents on their inventions. The process of getting a patent from the United States Patent and Trademark Office (USPTO) is called ‘patent prosecution', and that is our primary focus at Bold Patents. For many inventors and emerging businesses, protecting patents (as well as other areas of intellectual property) is a big deal and often causes a lot of stress and anxiety. Our goal at Bold Patents is to take the stress and worry off your shoulders and put it squarely on ours!

About ReelTime Rentals, Inc. d/b/a ReelTime Media: www.reeltime.com, is a publicly-traded company based in Seattle, WA (OTC PINK:RLTR). ReelTime Media provides end to end production capabilities and discount media purchasing that is redefining how companies are evaluating and purchasing their TV, radio, print, and other new media. ReelTime is also is in the business of developing, producing, and distributing Virtual Reality Content and technologies. We have an end to end production, editing, and distribution capabilities for internal and external projects. ReelTime Currently produces three ongoing series for the Samsung Gear VR platform and distributes them over numerous VR delivery portals including Gear VR, Oculus, Veer VR, HTC Vive, YouTube 360, Facebook, and others. ReelTime Media also publishes the book "It Was Always Me Edward Edwards the most Prolific Serial Killer of all time" which has been the subject of a cover story on People Magazine, Rolling Stone, In Touch, and a six-part series on Paramount network, www.itwasalwaysme.com.

Contact:

Barry Henthorn
ceo@reeltime.com

SOURCE: ReelTime Rentals, Inc.

ReleaseID: 603574

Processed cheese manufacturers are investing in strengthening distribution channels to retailers such as supermarkets and hypermarkets to keep up with demand during the covid-19 pandemic.

ROCKVILLE, MD / ACCESSWIRE / August 27, 2020 / The global processed cheeses market is anticipated to hit a valuation of US$ 24 billion valuation by the end of the forecast period from 2020 to 2029. The coronavirus pandemic is largely expected to adversely affect processed cheese sales. The closure of food services in many countries and the sudden drop in demand from commercial end-users are key factors hindering short term market prospects.

"Extensive branding efforts coupled with affordability are major factors that contribute to the sales of processed cheese. In addition, a wide range of flavor options are also boosting adoption among commercial users in the long term," says the FACT.MR report.

Processed Cheese Market- Key Takeaways

Private label cheeses are witnessing high adoption owing to low costs and ease of use in multiple cuisines.
Fast food applications contribute to substantial revenue growth, particularly owing to higher demand in emerging economies.
Europe is a major market for processed cheeses owing to the extensive use of cheese in most regional cuisines.

Request a sample of the report to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=157

Processed Cheese Market- Driving Factors

Attractive flavor options and versatility of use in multiple cuisines is a key factor driving adoption of processed cheeses.
Low price point coupled with the growth of the commercial fast food culture supports sales.

Processed Cheese Market- Major Restraints

Growing competition from gourmet and artisanal cheese is a major problem for processed cheese manufacturers.
Strict government regulations against additives such as sodium in foods is holding back market prospects.

COVID-19 Impact on Processed Cheese Market

The lockdown measures imposed by governments during the coronavirus pandemic have resulted in a significant dip in demand for processed cheese. The temporary closure of food service businesses during this period has had a major impact on the market. However, household consumption of processed cheese has witnessed growth during the lock down period, which provides manufacturers opportunities to partially recoup losses incurred during the outbreak. Recovery is likely to be gradual with lockdown restrictions being eased towards 2021.

Explore the global processed cheese market with 436 figures, 276 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/157/processed-cheese-market

Competitive Landscape

Lactalis, Modelez International, Le Groupe Bel, and Arla Foods are some of the leading processed cheeses manufacturers in the fragmented global market.

Players in the processed cheeses market are investing in the expansion of production capabilities through acquisitions and expansions. This enables them to keep up with rising demand and geographic penetration.

For example, St. Paul Group has entered a strategic agreement to acquire the processed and grated cheese business from Givaudan. Similarly, Lactalis Group has agreed to acquire the natural cheese division in Canada from Kraft Heinz for C$1.62 billion. Further, Fonterra Cooperative has announced its intentions to bolster production inn Australia following growth in demand.

About the Report

This study offers readers a comprehensive market forecast of the processed cheeses market. Global, regional and country-level analysis of the top industry trends impacting the processed cheeses market is covered in this FACT.MR study. The report offers insights on the processed cheeses market on the basis of type (blue cheese, brick cheese, camembert cheese, cheddar cheese, cottage cheese, cream cheese, mozzarella cheese, romano cheese, swiss cheese, and others), form (block, slice, spread, and spray), milk source (cattle milk, goat milk, and sheep milk), end use (household, HoReCa, F&B Processors, snack manufacturers, bakery & confectionery, sauces & condiments, ready meal, packaged food, and others) and distribution (direct sales, hypermarket/supermarket, club stores, discounters, grocery retailers, convenience stores, and online stores), across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Explore FACT.MR's Comprehensive Coverage of Food & Beverages Landscape

Cheese Market– Get the latest insights on the global cheese machine market through FACT.MR's report covering analysis for projection period (2017-2022).

Cheddar Cheese Market– FACT.MR's study on the global cheddar cheese market covers trends, tech innovations, players, and strategies for 2019-2029.

Natural Cheese Market– Obtain analysis on the global natural cheese market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2017-2022.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the food & beverages sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1588/processed-cheese-market-trends

SOURCE: Fact.MR

ReleaseID: 603601

MIRAMAR BEACH, FL / ACCESSWIRE / August 27, 2020 / Today, Abbott Realty Services is proud to announce the launch of a new military division, called "Abbott Realty Military Detachment." The new division is spearheaded by Michael and Cindy Sakalauski delivering exceptional real estate services to military families in Northwest Florida.

"With a combined 29 years of military service, it is in our DNA to serve. Representing both the Active and Reserve components, we are in a unique position to help military and civilian families alike because we understand the dynamics of life in and out of uniform. For years, we have successfully integrated our military experience and leadership into the real estate profession to provide top notch support and a quality experience," said Michael.

Abbott Realty Services is a family-owned and operated independent brokerage company in Northwest Florida. Since the 1950s, the Abbott family name has been synonymous with real estate along the Emerald Coast, starting with the original Abbott Realtor, William W. Abbott, Sr.. Today, husband and wife duo Nathan and Erin Abbott, and their sister Amanda, carry on the real estate tradition as the third generation of Abbott Realtors.

"We could not be happier to be joining forces with Team Sakalauski to serve military families across the Emerald Coast of Florida" said Nathan Abbott, Broker and Owner of Abbott Realty Services. "Mike is a Green Beret and Cindy is an officer of the United States Army. Their expertise working with military families, coupled with our expert native roots, allows the Abbott Realty Military Detachment to serve all the Armed Forces in high regard locally in real estate sales. We take pride in Raising a Higher Standard of Expectation as we salute our United States Armed Forces."

The Abbott Family started one of the first real estate companies in Destin in the early 70's and became the largest employer in Northwest Florida between the 80's to the late 90's. Nathan and Erin Abbott started their real estate careers in 2002 as a husband and wife team. They started expanding their team in 2010 as the Nathan Abbott Team before opening Abbott Realty Services. Their team of local experts continues to perform within the top 1% in real estate sales throughout Northwest Florida.

Abbott Realty currently serves the Emerald Coast from Pensacola to Destin, Santa Rosa Beach and Panama City Beach.

The ARS Military Detachment sales team can be reached at 850-629-8039 or MD@AbbottRealtyServices.com. We look forward to the opportunity to serve you!

About Nathan Abbott Team

The Nathan Abbott Team specializes in real estate services along Northwest Florida's Gulf Coast. They are natives to the area and would be honored to serve you. For more information, please call (850) 610-0110, or visit http://www.NathanAbbottTeam.com. The office is located at 9657 Highway 98 West, Miramar Beach, FL 32550.

For media inquiries, please call the NALA at 805.650.6121, ext. 361.

SOURCE: Nathan Abbott Team

ReleaseID: 603111

AVENTURA, FL / ACCESSWIRE / August 27, 2020 / Orbsat Corp (OTCQB:OSAT) ("Orbsat" or the "Company"), a global provider of communication solutions for connectivity to the world through next-generation satellite technology, today announced the closing of private placement of its securities. The Company raised gross proceeds of $933,000, before offering expenses, through sales of its 3-year 6% unsecured convertible promissory notes to accredited investors, including current and new shareholders.

The Company intends to use the offering proceeds for business development, investment in increased inventory and other strategic growth initiatives including market expansion and personnel recruitment in North America.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Additional details regarding the private placement are included in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2020.

About Orbsat Corp

Orbsat provides services and solutions to fulfill the rapidly growing global demand for satellite-based voice, high-speed data, tracking and IoT connectivity services. Building upon its long-term experience providing government, commercial, military and individual consumers with Mobile Satellite Services, Orbsat is positioned to capitalize on the significant opportunities being created by global investments in new and upgraded satellite networks. Orbsat's US and European based subsidiaries, Orbital Satcom and Global Telesat Communications, have provided global satellite connectivity solutions to more than 35,000 customers located in over 160 countries across the world.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding the expected use of proceeds from the private placement. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to the Company's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to the Company's reliance on third parties, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Contact for Orbsat Corp:

Michael Glickman
MWGCO, Inc.
917-397-2272
mike@mwgco.net

SOURCE: Orbsat Corp

ReleaseID: 603555

JACKSON CENTER, PA / ACCESSWIRE / August 27, 2020 / Halberd Corp. (OTC PINK:HALB) is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd's patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and signatures on the contract reflecting the agreed terms, is in process. Details will be released shortly.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly-traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Title

Application No.

Filing Date

Priority

Status

Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

n/a

Provisional application Pending

Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

n/a

Provisional application Pending

Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

4/21/2020

n/a

Provisional application Pending

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

ReleaseID: 603572

New 600kW Service Agreement for Food Production Facility Saving €300K Per Year in Energy Costs and 938 Tons of CO2 Emissions Annually.

VAN NUYS, CA / ACCESSWIRE / August 27, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that IBT Connecting Energies GmbH (www.ibtgroup.at), Capstone's exclusive distributor for Italy, signed a new Factory Protection Plan (FPP) long-term service contract for a Capstone C600 Signature Series microturbine (C600S) installed in a food production facility.

The C600S runs grid-connected using clean natural gas, and the co-generation application is the factory's prime energy source using power and steam for cooking cured meats, making this customer more competitive in their local market. Using Capstone technology, this customer is able to realize cost savings exceeding €300K per year and reduce CO2 emissions an estimated 938 tons per year.

During fiscal year 2020, Capstone Turbine saved end-use customers an estimated $219 million in annual energy costs and 368,000 tons of carbon. The fiscal 2020 results demonstrate continued progress in carbon savings, up 5% from the prior fiscal year, but were offset somewhat by cleaner electrical utility grids in the U.S. and Europe. A single Capstone powered combined heat and power (CHP) energy system can provide customers an annual energy savings of up to an estimated 40% while simultaneously meaningfully lowering their carbon footprint.

"We are very pleased to now see our European customers returning to more normal business operations, especially in Northern Italy, where this facility is located in Medesano," stated Jeff Foster, Capstone's Senior Vice President of Customer Service and Product Development. "While much of our service business continued supporting critical infrastructure customers during this unprecedented shutdown due to the COVID-19 pandemic, we are now beginning to see a return to the growth of our critical aftermarket FPP business across Europe," added Mr. Foster.

"This new contract shows the resiliency of the Italian people after the devastating impact of the COVID-19 pandemic and brings hope for continued recovery across the rest of the world," stated Darren Jamison, President and Chief Executive Officer of Capstone Turbine Corporation. "IBT has been a long-term partner of Capstone, and we are excited to see their business recovery and how our new world view of energy solutions highlighted by the impacts of COVID-19, will continue to drive customers to see the value in Capstone clean and reliable distributed energy solutions," concluded Mr. Jamison.

Capstone is committed to saving customers money by improving the energy efficiency of its operations around the world. Microturbine based high-efficiency energy systems provide an economic benefit while also reducing carbon and global emissions in order to create a better environment and help end-use customers achieve their carbon reduction goals while also providing energy resiliency.

Capstone's innovative Factory Protection Plan, or FPP, is a comprehensive maintenance program designed to give financial peace of mind to Capstone customers by providing product life cycle costs at a fixed rate for both scheduled and unscheduled maintenance for the life of the microturbine system. Additionally, the recently updated FPP protects microturbine customers from potentially dramatic future increases in life cycle costs associated with changes in replacement spare parts pricing, commodity price increases, import tariffs, and interest rate changes.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 603579

LOS ANGELES, CA / ACCESSWIRE / August 27, 2020 / Applied Energetics, Inc. (OTCQB:AERG), ("Applied Energetics" or the "Company"), a provider of innovative directed energy solutions, ultra-short pulse lasers, and related technologies for the national security, medical technology, and advanced manufacturing markets, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 12:20 PM PDT / 3:20 PM EDT. Gregory J. Quarles, Ph.D., chief executive officer of Applied Energetics will be presenting to a live audience.

Applied Energetics, Inc., is a pure play in directed energy, and a pioneer in photonic and high-voltage energetics technology. The company utilizes its proprietary knowledge of high-performance lasers, high-voltage electronics, advanced adaptive optics and atmospheric and plasma energy interactions to develop cutting edge technologies and innovative solutions for critical military missions. Applied Energetics technology is vastly different from conventional directed energy weapons. Applied Energetics is the exclusive developer of Laser Guided Energy (LGE™) and Laser Induced Plasma Channel (LIPC™) technologies. LGE uses Ultra-Short Pulse (USP) laser technology to combine the speed and precision of lasers with the overwhelming impact on targeted threats with high-voltage electricity. The Company has protected and controls what it believes to be the enabling intellectual property through 26 approved U.S. Patents and 11 Government Sensitive Classified U.S. Patents.

As Applied Energetics moves toward the future, our corporate strategic roadmap builds upon the significant value of the company's USP capabilities and key intellectual property, including LGE and LIPC, to offer our prospective partners, co-developers and system integrators a variety of next-generation Ultra Short-Pulse and frequency-agile optical sources from the ultraviolet to the far infrared portion of the electromagnetic spectrum to address numerous challenges within the military, medical device, biomedical, and advanced manufacturing market sectors.

As of March 4, 2020, AERG executed a contract agreement with the US Army to investigate Standoff Electronic Denial systems using ultrashort pulse lasers. The final report for this Phase I contract was submitted on July 3, 2020 and the US Army subsequently accepted the Phase I Final Report and invited AERG to participate in the Phase II process through the submission of a Phase II proposal, which was subsequently submitted and accepted on August 10, 2020, and we await the review of this proposed technological advance for the US Army Standoff Electronic Denial topic. Applied Energetics continues to engage various communities with research, development and deliverable proposals focused primarily on the applications of ultrashort pulse laser and optical systems.

Announced company milestones and initiatives include the following:

Experienced, and highly innovative management team assembled May/June 2019
Strong IP Portfolio: Over $50M of public and privately funded IP with portfolio of 26 patents and 11 applications held under government secrecy orders
Active Partner with three of the leading universities in Optical Source technologies
Executed and completed contract award started March 2020 with U.S Army for Stand-off Electronic Denial
Multiple complimentary research proposals submitted over the past 12 months.

For additional information about Applied Energetics, please visit the company's website at www.aergs.com

The LD 500 will take place on September 1st through the 4th.

Register here: https://ld-micro-conference.events.issuerdirect.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Applied Energetics' profile here: http://www.ldmicro.com/profile/AERG

Profiles powered by LD Micro – News Compliments of Accesswire

About Applied Energetics, Inc.

Applied Energetics, Inc., "AE" based in Tucson, Arizona, specializes in development and manufacture of advanced high-performance lasers, high voltage electronics, advanced optical systems, and integrated guided energy systems for defense, aerospace, industrial, and scientific customers worldwide. Applied Energetics pioneered and holds all crucial intellectual property rights to the development and use of Laser Guided Energy (LGE™) technology and related solutions for commercial, defense and security applications, and are protected by 26 patents and 11 additional Government Sensitive Patent Applications "GSPA". The company's 11 GSPA's are held under secrecy orders of the US government and allow AE greatly extended protection rights.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Applied Energetics Investor Relations
Cameron Associates, Inc.
Kevin McGrath, Managing Director
T: 212-245-4577
kevin@cameronassoc.com

FORWARD LOOKING STATEMENTS

Certain statements in this press release constitute forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that do not relate solely to the historical or current facts and can be identified by the use of forward-looking words such as "may", "believe", "will", "expect", "project", "anticipate", "estimates", "plans", "strategy", "target", "prospects" or "continue", and words of similar meaning. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial condition and may cause our actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. We do not assume any obligation to update these forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting such forward-looking statements.

SOURCE: Applied Energetics, Inc. via LD Micro

ReleaseID: 603573

Tetra defines CBD Metabolism in Humans Following QIXLEEF™ Inhalation
Data from metabolite study provides explanation for inhalation as a safe route of administration

OTTAWA, ON / ACCESSWIRE / August 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has mapped out CBD metabolites in humans who were administered QIXLEEF™ by vaporization. QIXLEEF™ is Tetra's first-generation therapeutic for treating uncontrolled pain in advanced cancer patients.

Defining THC and CBD metabolites in human plasma is a critical step for the US Food and Drug Administration and Health Canada to characterize the safety profile of the drug product in patients consuming cannabis. As previously announced, Tetra had launched a study to quantify the levels of cannabinoid metabolites and precursors as well as minor cannabinoids in the plasma samples of individuals who received QIXLEEF™ in its clinical trials. The bioanalysis of these human plasma samples will allow Tetra to better understand how THC and CBD are degraded in humans and how long these compounds remain in the blood, as well as the differences between the two inhalation routes (smoking vs vaping) of consuming QIXLEEF™.

Tetra successfully developed and validated methods to characterize the major CBD metabolites (7-OH-CBD and 7-COOH-CBD) in humans, which are known to induce liver injury above a certain threshold of circulating plasma levels. The data demonstrated that the degradation of CBD during QIXLEEF™ inhalation leads to very low amounts of 7-OH-CBD and 7-COOH CBD and a faster degradation profile compared to oral administration.

These data emphasize the benefits of QIXLEEF™ as an inhaled cannabis-based drug. QIXLEEF™ not only has a safe and well tolerated profile, but also has a rapid and high degree of absorption favouring a higher efficacy at a lower dose, compared to oral administration.

"The rapid and relatively high absorption of CBD and the low amounts of CBD metabolites in humans support our claim that inhalation provides a superior safety profile for CBD administration over oral administration. The efficiency of QIXLEEF™ absorption combined with its greater safety profile will offer a unique solution to patients seeking relief from pain due to various diseases and illnesses", said Dr. Guy Chamberland, Tetra CEO and CRO.

About QIXLEEF™

QIXLEEF™, first-generation therapeutic for treating uncontrolled pain in advanced cancer patients is a dried cannabis flower bud derived therapeutic that contains no excipients or other nonmedicinal ingredients. PLENITUDE© is the Company's clinical trial for its investigational therapeutic QIXLEEF™. The second-generation cannabinoid therapeutic, a cannabinoid synthetic version of QIXLEEF™, is called CAUMZ™.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:
Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
investors@tetrabiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

ReleaseID: 603578

BASKING RIDGE, NJ / ACCESSWIRE / August 27, 2020 / Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that management has been invited to present at the LD 500 virtual investor conference being held September 1-4, 2020.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, is scheduled to present on Tuesday, September 1, 2020 at 11:40 a.m. ET and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the day.

The presentation will be webcast live and available for replay here and via the events section of the company's website at www.caladrius.com.

To schedule a virtual one-on-one meeting with Caladrius, you may submit your request to register for the conference here or contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events.

To view Caladrius's LD Micro profile, please visit: http://www.ldmicro.com/profile/CLBS

Profiles powered by LD Micro – News Compliments of Accesswire

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company's current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI") based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction ("CMD"); and CLBS14, a Regenerative Medicine Advanced Therapy ("RMAT") designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the "FDA") a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina ("NORDA"). For more information on the company, please visit www.caladrius.com.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com

SOURCE: Caladrius Biosciences via LD Micro

ReleaseID: 603476